Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Luxna Biotech Co., Ltd. logo — Advancing Antisense Therapeutics: Preclinical-stage ASO deve...

Luxna Biotech Co., Ltd.

Advancing Antisense Therapeutics: Preclinical-stage ASO developer leveraging proprietary XNAs & LuxiAP™ platform.

Founded 2017 Japan Japan 9 employees Venture round Total: $880.00M Biotechnology, Health Care

General Information

Company Name Luxna Biotech Co., Ltd.
Founded Year 2017
Location Japan Japan
Employees 9
Industries Biotechnology, Health Care
Funding Stage Venture round
Business Model B2B, Platform
Revenue Model Licensing, Project Based, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Luxna Biotech Co., Ltd.. To contact Luxna Biotech Co., Ltd., visit luxnabiotech.co.jp.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Luxna Biotech Co., Ltd. compare?

A PDF of Luxna Biotech Co., Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Luxna Biotech Co., Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Luxna Biotech Co., Ltd.

Luxna Biotech Co., Ltd. is making significant strides in the biotechnology sector, with its focus on developing antisense therapeutics. Founded in 2017 and headquartered in Japan, the company leverages its proprietary LuxiAP™ platform to create preclinical-stage antisense oligonucleotides (ASO) that are safer and more efficacious, especially for neurological applications.

The company specializes in unique modified nucleic acids and has established several collaborations with pharmaceutical companies. These efforts are bolstered by Luxna Biotech's work on a promising ASO pipeline targeting conditions like ALS, spinal cord injury, and hearing loss.

Recent interest from investors, exemplified by a Venture Round investment on 01 December 2021 from Healthcare Innovation, underscores the potential seen in Luxna's approach. The company actively seeks partnerships for both platform collaboration and early-stage co-development opportunities, making it an attractive prospect for investors interested in innovative solutions within the health care and biotechnology industries.

Business keywords: Antisense Therapeutics, Preclinical Drug Development, Proprietary Nucleic Acids, Bridged Nucleic Structures, Neurological Diseases, Gapmer Technology, CNS ASO Drug Platform, ALS Treatment Development, Spinal Cord Injury Solutions, Hearing Loss Innovations, Biotech Pharmaceutical Collaborations, ASO Pipeline Development, Co-development Alliances, Neurotoxicity Minimization

Services & Products

Nucleic Acid Medicine Development
Licensing of Modified Nucleic Acid Technology
Joint Drug Development Ventures
Research and Development

Target Customers

Pharmaceutical Companies Biotechnology Researchers Healthcare Providers Patients Battling Illnesses

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 1
Healthcare Innovation
Healthcare Innovation
01 Dec 2021
Series A ¥650.00M 5
Mizuho Capital Senshu Ikeda Capital Osaka University Venture Capital
Mizuho Capital, Senshu Ikeda Capital +3
10 Feb 2020
Debt Financing ¥130.00M 1
Japan Policy Finance
Japan Policy Finance
01 Nov 2019
Seed Round ¥100.00M 1
Osaka University Venture Capital
Osaka University Venture Capital
01 Mar 2018

Luxna Biotech Co., Ltd. Alternatives & Competitors

Luxna Biotech Co., Ltd. vs
Novoron Bioscience
Novoron Bioscience United States

Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spi...

Seed
17 employees
Biopharma, Biotechnology

FAQ About Luxna Biotech Co., Ltd.

Advancing Antisense Therapeutics: Preclinical-stage ASO developer leveraging proprietary XNAs & LuxiAP™ platform.
Luxna Biotech Co., Ltd. was founded in 2017.
Luxna Biotech Co., Ltd. is headquartered in Japan.
Luxna Biotech Co., Ltd. operates in Biotechnology and Health Care. Its work centres on Antisense Therapeutics, Preclinical Drug Development, Proprietary Nucleic Acids and Bridged Nucleic Structures. Its customers include Pharmaceutical Companies, Biotechnology Researchers and Healthcare Providers.
Luxna Biotech Co., Ltd. has a B2B and Platform business model. Its revenue comes from Licensing, Project Based and Performance Based.
Luxna Biotech Co., Ltd. has approximately 9 employees.
Luxna Biotech Co., Ltd. has completed 4 funding rounds, raising a total of $880.00M. The latest funding stage is Venture round.
Luxna Biotech Co., Ltd. offers: Nucleic Acid Medicine Development, Licensing of Modified Nucleic Acid Technology, Joint Drug Development Ventures, Research and Development.
Top alternatives and competitors to Luxna Biotech Co., Ltd. include Novoron Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Luxna Biotech Co., Ltd. and Novoron Bioscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Luxna Biotech Co., Ltd., https://bouncewatch.com/company/luxna-biotech, updated 11 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout